Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

Pfizer Inc. announced longer-term follow-up results from the phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi (encorafenib) in combination with Mektovi ...

The Phase 2 PHAROS trial is an open-label, multicenter, single arm study examining BRAFTOVI + MEKTOVI combination therapy in treatment-naive and previously treated patients with BRAF V600E-mutant ...

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene and the structure of the BRAF protein ...

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

The firm's assessment follows the release of preliminary data on C4 Therapeutics' CFT1946, a treatment for solid tumors with BRAF V600X mutations. The data, presented in an abstract at the European ...

The company presented three-year follow-up data from a Phase 2 study on Saturday looking at patients with BRAF V600E-mutant metastatic non-small cell lung cancer who received Braftovi and another ...